Icecure Medical Ltd
ICCM0.935USD
-0.075-7.39%
取引時間 （ET）15分遅れの株価
54.83M時価総額
損失額直近12ヶ月PER
詳細情報 Icecure Medical Ltd 企業名
Icecure Medical Ltd is an Israel-based company that is engaged in the healthcare sector. The Company operates as commercial stage medical device company focusing on the research, development and marketing of cryoablation systems, disposables and technologies based on liquid nitrogen, or LN2, for treating tumors. Cryoablation technology is a minimally invasive alternative to surgical intervention, for tumors, including those found in breast, lungs, kidneys, bones and other indications. Company's lead product is ProSense system, a single probe system, but in addition the Company developed an additional multi probe system that is expected to have the ability to freeze several tumors simultaneously or larger tumors, named MultiSense system, which has not yet been commercialized.
企業情報
企業コードICCM
会社名Icecure Medical Ltd
上場日Feb 02, 2011
最高経営責任者「CEO」Mr. Eyal Shamir
従業員数64
証券種類Ordinary Share
決算期末Feb 02
本社所在地7 Ha'eshel St.
都市CAESAREA
証券取引所NASDAQ Capital Market Consolidated
国Israel
郵便番号3079504
電話番号97246230333
ウェブサイトhttps://icecure-medical.com/
企業コードICCM
上場日Feb 02, 2011
最高経営責任者「CEO」Mr. Eyal Shamir
役員一覧
会社名
会社名/ポジション
ポジション
株式保有
変動額
Mr. Eyal Shamir
Mr. Eyal Shamir
Chief Executive Officer, Director
Chief Executive Officer, Director
590.31K
+13.38%
Mr. Ronen Tsimerman
Mr. Ronen Tsimerman
Vice President - Finance, Vice President - Operations
Vice President - Finance, Vice President - Operations
355.08K
+15.46%
Mr. Naum Muchnik
Mr. Naum Muchnik
Vice President - Research & Development
Vice President - Research & Development
140.42K
+33.36%
Mr. Oded Tamir
Mr. Oded Tamir
External Director
External Director
20.00K
+100.00%
Ms. Elisabeth Sadka
Ms. Elisabeth Sadka
Vice President-Clinics, Regulations and Quality Assurance
Vice President-Clinics, Regulations and Quality Assurance
--
--
Ms. Tlalit Bussi Tel-Tzure
Ms. Tlalit Bussi Tel-Tzure
Vice President - Business Development & Marketing
Vice President - Business Development & Marketing
--
--
Ms. Sharon Levita
Ms. Sharon Levita
External Director
External Director
--
--
Mr. Doron Birger
Mr. Doron Birger
Independent Director
Independent Director
--
--
Mr. Yaacov Goldman
Mr. Yaacov Goldman
External Director
External Director
--
--
Mr. Ron Abraham Mayron
Mr. Ron Abraham Mayron
Chairman of the Board
Chairman of the Board
--
--
会社名
会社名/ポジション
ポジション
株式保有
変動額
Mr. Eyal Shamir
Mr. Eyal Shamir
Chief Executive Officer, Director
Chief Executive Officer, Director
590.31K
+13.38%
Mr. Ronen Tsimerman
Mr. Ronen Tsimerman
Vice President - Finance, Vice President - Operations
Vice President - Finance, Vice President - Operations
355.08K
+15.46%
Mr. Naum Muchnik
Mr. Naum Muchnik
Vice President - Research & Development
Vice President - Research & Development
140.42K
+33.36%
Mr. Oded Tamir
Mr. Oded Tamir
External Director
External Director
20.00K
+100.00%
Ms. Elisabeth Sadka
Ms. Elisabeth Sadka
Vice President-Clinics, Regulations and Quality Assurance
Vice President-Clinics, Regulations and Quality Assurance
--
--
Ms. Tlalit Bussi Tel-Tzure
Ms. Tlalit Bussi Tel-Tzure
Vice President - Business Development & Marketing
Vice President - Business Development & Marketing
--
--
収益内訳
通貨: USD更新時刻: Sun, Jul 6
通貨: USD更新時刻: Sun, Jul 6
FY2024
FY2023
FY2022
FY2021
FY2020
データなし
地域別USD
会社名
収益
比率
Other
1.46M
44.24%
United States
870.00K
26.44%
Japan
481.00K
14.62%
India
413.00K
12.55%
China
41.00K
1.25%
Israel
30.00K
0.91%
事業別
地域別
データなし
株主
更新時刻: Sun, Jul 27
更新時刻: Sun, Jul 27
株主統計
種類
株主統計
株主統計
比率
Haixiang (Li)
44.03%
Shamir (Eyal)
1.01%
Tsimerman (Ronen)
0.60%
Mayron (Ron)
0.47%
Tel-Tzure (Tlalit Bussi)
0.33%
Other
53.55%
株主統計
株主統計
比率
Haixiang (Li)
44.03%
Shamir (Eyal)
1.01%
Tsimerman (Ronen)
0.60%
Mayron (Ron)
0.47%
Tel-Tzure (Tlalit Bussi)
0.33%
Other
53.55%
種類
株主統計
比率
Individual Investor
47.49%
Investment Advisor
0.12%
Investment Advisor/Hedge Fund
0.09%
Venture Capital
0.04%
Research Firm
0.03%
Other
52.24%
機関投資家保有株
更新時刻: Tue, Jul 1
更新時刻: Tue, Jul 1
報告期間
機関投資家数
保有株式数
比率
変動額
2025Q2
45
28.04M
47.77%
+71.20K
2025Q1
44
28.01M
47.78%
-9.18K
2024Q4
41
27.61M
48.82%
+489.62K
2024Q3
42
27.95M
49.54%
-2.17M
2024Q2
41
27.48M
56.81%
+3.00M
2024Q1
39
27.22M
56.29%
+2.63M
2023Q4
40
21.73M
47.63%
-6.82M
2023Q3
37
21.68M
47.52%
-6.84M
2023Q2
36
21.65M
47.45%
-6.97M
2023Q1
32
21.72M
47.62%
-6.97M
詳細を見る
株主動向
会社名
保有株式数
比率
変動額
変動率
日付
Haixiang (Li)
25.85M
44.09%
--
--
Dec 31, 2024
Shamir (Eyal)
590.31K
1.01%
+69.67K
+13.38%
Mar 24, 2025
Tsimerman (Ronen)
355.08K
0.61%
+47.55K
+15.46%
Mar 24, 2025
Mayron (Ron)
278.02K
0.47%
+55.45K
+24.91%
Mar 24, 2025
Tel-Tzure (Tlalit Bussi)
191.81K
0.33%
+35.32K
+22.57%
Mar 24, 2025
Levav (Shay)
141.86K
0.24%
+37.69K
+36.18%
Mar 24, 2025
Muchnik (Naum)
140.42K
0.24%
+35.13K
+33.36%
Mar 24, 2025
Huang (Yang)
113.44K
0.19%
+40.12K
+54.72%
Mar 24, 2025
Dotan (Merav Nir)
88.94K
0.15%
+30.84K
+53.09%
Mar 24, 2025
Malik (Galit)
79.67K
0.14%
+23.32K
+41.40%
Mar 24, 2025
詳細を見る
関連ETF
銘柄名
比率
データなし
配当金
過去5年間の配当金総支払額は
0.00
米ドルである。
日付
配当金
権利確定日
支払日
配当落ち日
データなし
株式分割
日付
種類
比率
データなし
日付
種類
比率
データなし
